Answers are grounded in this paper and cite their sources.
Case report demonstrates successful control of bullous pemphigoid and psoriasis using apremilast, highlighting its efficacy for coexisting autoimmune skin disorders.
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. Figure S1: Clinical course of the present case. Erythema and tense blisters improved with minocycline, nicotinic acid, apremilast and topical corticosteroids. The rash relapsed as apremilast was discontinued and improved with the resumption of apremilast. BPDAI: bullous pemphigoid disease area index, BP180 Ab: anti-BP180NC16a antibody levels. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Kumagai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: